logo-loader

Affymax, Inc.

Receive alerts
Market:
NASDAQ
Market Cap:
-
Price
-
Change
-
52 weeks high
-
52 weeks low
-

In brief

Affymax, Inc. is a biopharmaceutical company engaged in developing drugs to improve the treatment of serious and often life-threatening conditions. Its product candidate, peginesatide, is for the treatment of anemia in chronic kidney disease patients on dialysis. Peginesatide is a synthetic peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells.